Survival of intravenous chemotherapy infusion sites
- PMID: 2223586
- PMCID: PMC1971472
- DOI: 10.1038/bjc.1990.351
Survival of intravenous chemotherapy infusion sites
Abstract
Factors associated with the failure of intravenous infusions due to phlebitis and extravasation were studied with 218 infusions delivering cytotoxic drugs. The survival rate of these infusions was not significantly different from that of 56 non-cytotoxic infusions in oncology patients. Although survival analysis indicated that cisplatin was associated with longer survival, this was probably an artifact caused by this drug usually being preceded by 24 h prehydration. Multivariate analysis indicated that etoposide was the only drug associated with decreased infusion survival and that bleomycin, cyclophosphamide, doxorubicin, ifosphamide, methotrexate, treosulphan and 5-fluorouracil had no significant effects. Also age of patient, infusion site and flow rate had no effects but survival was shorter in women. Follow-up indicated that failure of an infusion tended to result in loss of the vein. It is suggested that irritancy of the large volumes of intravenous fluids given to hydrate these patients rather than the cytotoxic drugs was the main factor reducing the survival of these infusions.
Similar articles
-
Failure of intravenous infusions from extravasation and phlebitis.Anaesth Intensive Care. 1989 Nov;17(4):433-9. doi: 10.1177/0310057X8901700406. Anaesth Intensive Care. 1989. PMID: 2596677
-
Transdermal nitroglycerin for the prevention of intravenous infusion failure due to phlebitis and extravasation.Ann Pharmacother. 2000 Oct;34(10):1189-92. doi: 10.1345/aph.18188. Ann Pharmacother. 2000. PMID: 11054989 Review.
-
Failure of intravenous infusions in neonates.J Paediatr Child Health. 1991 Jun;27(3):175-9. doi: 10.1111/j.1440-1754.1991.tb00381.x. J Paediatr Child Health. 1991. PMID: 1909534
-
[Risk factors for the development of phlebitis in peripheral infusions].Ned Tijdschr Geneeskd. 1998 Feb 21;142(8):405-9. Ned Tijdschr Geneeskd. 1998. PMID: 9562775 Dutch.
-
Reducing infusion failure: a pharmacologic approach--a review.J Intraven Nurs. 1996 Mar-Apr;19(2):89-97. J Intraven Nurs. 1996. PMID: 8852169 Review.
Cited by
-
Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice.Br J Cancer. 2007 Mar 26;96(6):937-43. doi: 10.1038/sj.bjc.6603640. Epub 2007 Feb 27. Br J Cancer. 2007. PMID: 17325706 Free PMC article.
-
Potential for extending survival of peripheral intravenous infusions.BMJ. 1992 Mar 7;304(6827):619-24. doi: 10.1136/bmj.304.6827.619. BMJ. 1992. PMID: 1472179 Free PMC article. Review. No abstract available.
-
The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.Br J Cancer. 2003 Jul 21;89(2):357-62. doi: 10.1038/sj.bjc.6601022. Br J Cancer. 2003. PMID: 12865930 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources